Budget impact analysis of apixaban to treat and prevent venous thromboembolism in Italy
DOI:
https://doi.org/10.7175/fe.v17i3.1280Keywords:
Apixaban, Venous thromboembolism, Budget Impact, NOACAbstract
BACKGROUND: Venous thromboembolism (VTE), a collective term for deep vein thrombosis (DVT) and pulmonary embolism (PE), is a serious vascular condition associated to high economic and clinical burden. Apixaban, a Novel Oral Anticoagulant (NOAC) has shown non-inferiority efficacy versus the current standard of care (low molecular weight heparin [LMWH]/vitamin K antagonist [VKA]) in the acute treatment and prevention of VTE and a significant reduction in the risk of bleeding.AIM: Evaluate the economic impact of the use of apixaban for treatment and prevention of DVT and PE from the perspective of the Italian National Health System (NHS).
METHODS: A budget impact model was adapted in order to compare clinical outcomes and economic consequences associated to apixaban vs. LMWH/VKA and others NOACs over a three-year time horizon in the Italian setting. In the analysis two scenario were compared: status quo scenario without apixaban and an alternative scenario with apixaban. Only direct healthcare costs have been considered.
RESULTS: Assuming a population of patients receiving apixaban over the first 3 years equal to 20,957, the introduction of apixaban is associated to an incremental saving of € 821,748 in the first years, € 1,250,454 in the second year, and € 1,866,466 in the third year. The total net saving over the 3-year period is € 3,938,668, which is a 2.47% decrease from the total budget for the status quo scenario without apixaban. This saving is mainly due to reduced VTE events and bleeds by apixaban. Indeed apixaban is associated with less VTE events (both fatal and non-fatal), less major bleeding and less Clinical Relevant Non Major (CRNM) bleeding with a total of 52 fatal events avoided.
CONCLUSIONS: The listing of apixaban for the treatment of VTE (both DVT and PE) and the prevention of recurrent VTE provides both significant clinical advantages, in terms of deaths and events avoided, and economical advantages, consisting in a reduction in the total expenditure on the Italian NHS.
References
Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy 2009; 29: 943-53; http://dx.doi.org/10.1592/phco.29.8.943
White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-I8; https://doi.org/10.1161/01.CIR.0000078468.11849.66
Spencer FA, Emery C, Lessard D, et al. The Worchester Venous Thromboembolism Study. A population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-7; https://doi.org/10.1111/j.1525-1497.2006.00458.x
Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-93; https://doi.org/10.1001/archinte.158.6.585
Cimminiello C, Filippi A, Mazzaglia G, et al. Venous thromboembolism in medical patients treated in the setting of primary care: a nationwide case-control study in Italy. Thromb Res 2010; 126: 367-72; https://doi.org/10.1016/j.thromres.2010.07.005
Prandoni P. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations. Thromb Res 2014; 134: 227-33; https://doi.org/10.1016/j.thromres.2014.05.013
Kearon C, Akl EA, Comerota AJ, et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): 419-94; http://dx.doi.org/10.1378/chest.11-2301
Ansell J, Hirsh J, Hylek E, et al.; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 160S-198S; https://doi.org/10.1378/chest.08-0670
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315-52; https://doi.org/10.1016/j.chest.2015.11.026
Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One 2015; 10: e0144856; https://doi.org/10.1371/journal.pone.0144856
Comunicato relativo al medicinale per uso umano «Eliquis» (15A03834). GU Serie Generale n.118 del 23-5-2015
Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808; https://doi.org/10.1056/NEJMoa1302507
Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708; https://doi.org/10.1056/NEJMoa1207541
Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health 2007; 10: 336-47; https://doi.org/10.1111/j.1524-4733.2007.00187.x
Sullivan SD, Mauskopf JA, Augustovski F, et al., Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014; 17: 5-14; https://doi.org/10.1016/j.jval.2013.08.2291
ISTAT – Istituto Nazionale di Statistica. Available at: http://dati.istat.it/Index.aspx (last accessed April 2016)
Cohen AT, Hamilton M, Bird A, et al. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One 2016; 11: e0160064; https://doi.org/10.1371/journal.pone.0160064
Task Force sull’Embolia Polmonare. Linee guida per la diagnosi ed il trattamento dell’embolia polmonare acuta. Ital Heart J Suppl 2001; 2: 161-99
Mennini F, Russo S, Marcellusi A. Budget impact analysis resulting from the use of dabigatran etexilate in preventing stroke in patients with non-valvular atrial fibrillation in Italy. Farmeconomia. Health economics and therapeutic pathways 2012;13: 121-31; https://doi.org/10.7175/fe.v13i3.268
Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). ThrombHaemost 2011; 106: 868-76; https://doi.org/10.1160/TH11-05-0358
Agnelli G, Verso M, Ageno W, et al.; MASTER investigators. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res 2008; 121: 605-10; https://doi.org/10.1016/j.thromres.2007.06.009
Tariffe delle prestazioni di assistenza ospedaliera per acuti (sistema DRG). Supplemento ordinario n. 8 alla Gazzetta Ufficiale Serie generale - n. 23 del 28-1-2013
Torbicki A, Perrier A, Konstantinides S, et al.; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-315; https://doi.org/10.1093/eurheartj/ehn310
Nomenclatore tariffario dell’assistenza specialistica ambulatoriale. Tariffa Unica Convenzionale. Edizione 2013
Ministero della Salute. Progetto Mattoni SSN. Pronto Soccorso e Sistema 118. “Proposta metodologica per la valutazione dei costi dell’emergenza” Roma 2007
Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013; 347: f5133; https://doi.org/10.1136/bmj.f5133
National Institute for Health and Care Excellence. Final Appraisal determination – Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. Technology appraisal guidance [TA341]. Available at: https://www.nice.org.uk/guidance/ta341 (last accessed April 2016)
Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011; 14: 417-28; https://doi.org/10.1016/j.jval.2011.04.002
Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Hoboken, NJ: Wiley, 2004
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
